Fabio Iwamoto, MD,
Open to Accrual
Brain [BN]
Malignant Glioma
III
No
To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) significantly prolongs overall survival (OS) vs. standard chemoradiotherapy with temozolomide in patients with newly diagnosed GBM (GBM) with MGMT promoter methylation.
Histopathologicallyproven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma)confirmed by central pathology review. MGMT promoter with methylationconfirmed by central pathology review. IDH mutation testing by atleast one method must be performed as part of standard of care and nomutation must be found.
306
NRG-BN011 Study Overview by Fabio Iwamoto (July 2023)
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.